Drug Profile
CP 800569
Alternative Names: CP-800569Latest Information Update: 21 Apr 2009
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperlipidaemics; Cardiovascular therapies; Propanolamines
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 06 Feb 2008 CP 800569 is still in phase I development for Atherosclerosis in USA
- 20 Nov 2006 Phase-I clinical trials in Atherosclerosis in USA (unspecified route)